CILIATECH is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. The company’s groundbreaking concept CID (Cilio-scleral Interpositioning Device) is the first implant in the industry to reduce IOP without penetrating the anterior chamber or creating subconjunctival filtration. Clinical trials show IOP is reduced by 33% at 12 months (89% patients drop free, no reoperation needed) and without ECL risk.
